Global Stem Cell Umbilical Cord Blood Market 2015-2019

幹細胞臍帯血(UCB)の世界市場2015-2019

◆タイトル:Global Stem Cell Umbilical Cord Blood Market 2015-2019
◆商品コード:IRTNTR6649
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年8月19日
◆ページ数:79
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、幹細胞臍帯血の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、幹細胞臍帯血の世界市場規模及び予測、用途別分析、需要先別分析、臍帯血収集/加工/保存プロセス、米国FDA承認臍帯血製品、市場シェア、地域別分析、購買基準、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Stem Cell UCB
UCB is the blood that remains in the placenta and the attached umbilical cord after childbirth. UCB contains stem cells that are unique, smart, and are capable of treating several life-threatening diseases. They are used in the treatment of hematopoietic and genetic disorders. The placental blood can produce 10 times more quantity of stem cells compared to the umbilical cord, which can in turn be used for the treatment of an adult patient. The cord blood that is collected during the childbirth is stored and cryopreserved. The storage of the cord blood can be done at private cord blood banks or public cord blood banks. This preserved blood can be used for the transplantation, and treatment of diseases at the later stages of life.

Technavio’s analysts forecast the global stem cell UCB market to grow at a CAGR of 30.36% over the period 2014-2019.

[Covered in this Report]
The report covers the present scenario and the growth prospects of the global stem cell UCB market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the banking and utilization of UCB stem cells for the treatment of various disorders, such as cancers, blood disorders, metabolic disorders, immune diseases, and others.

Technavio’s report, Global Stem Cell UCB Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global stem cell UCB market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Caladrius Biosciences
• Celgene
• Mesoblast
• Pluristem Therapeutics

[Other Prominent Vendors]
• Athersys
• CHA Bio & Diostech
• Cytori Therapeutics
• Nuo Therapeutics
• Ocata Therapeutics
• Opexa Therapeutics
• Osiris Therapeutics
• Teva Pharmaceuticals
• United Therapeutics

[Market Driver]
• Effective Treatment of Life-threatening Diseases
• For a full, detailed list, view our report

[Market Challenge]
• Stringent Regulations
• For a full, detailed list, view our report

[Market Trend]
• Growing Public Awareness
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Process of Collection, Processing, and Storage of Cord Blood Cells
06.1 Donor Evaluation
06.2 Collection Methods
06.3 Processing and Storage Methods
06.4 Sample Retention and Length of Storage

07.Facts: Cord Blood Units

08.US FDA Approved Stem Cell UCB Product
08.1 Hemacord
08.1.1 Mechanism of Action
08.1.2 Side Effects

09.Pipeline Analysis
09.1 Information on Pipeline Candidates
09.1.1 PDA-002
09.1.2 PDA-001
09.1.3 PLX-PAD
09.1.4 PLX-R18

10.Market Landscape
10.1 Market Overview
10.2 Market Size and Forecast
10.3 Five Forces Analysis

11.Market Segmentation by Application
11.1 Cancers
11.2 Blood Disorders
11.3 Metabolic Disorders
11.4 Immune Disorders
11.5 Others

12.Market Segmentation by Storage
12.1 Public Cord Blood Bank
12.2 Private Cord Blood Bank
12.3 Public-Private Cord Blood Banks

13.Harmonization of Biobanking

14.Market Segmentation by End-user
14.1 Research Institutes
14.2 Pharmaceutical Companies
14.3 Biobanks
14.4 Hospitals

15.Geographical Segmentation
15.1 Stem Cell UCB Market in Americas
15.1.1 Market Size and Forecast
15.2 Stem Cell UCB Market in EMEA
15.2.1 Market Size and Forecast
15.3 Stem Cell UCB Market in APAC
15.3.1 Market Size and Forecast

16.Buying Criteria

17.Market Growth Drivers

18.Drivers and their Impact

19.Market Challenges

20.Impact of Drivers and Challenges

21.Market Trends

22.Trends and their Impact

23.Vendor Landscape
23.1 Competitive Scenario
23.1.1 Key News
23.1.2 Mergers and Acquisitions
23.2 Market Share Analysis 2014
23.2.1 Caladrius Biosciences
23.2.2 Celgene Corp.
23.2.3 Mesoblast Ltd.
23.2.4 Pluristem Therapeutics
23.3 Other and Future Prominent Vendors

24.Global Stem Cell UCB Market: Key Takeaways

25.Key Vendor Analysis
25.1 Caladrious
25.1.1 Key Facts
25.1.2 Business Overview
25.1.3 Business Segmentation by Revenue 2014
25.1.4 Business Segmentation by Revenue 2013 and 2014
25.1.5 Geographical Segmentation by Revenue 2014
25.1.6 Business Strategy
25.1.7 Recent Developments
25.1.8 SWOT Analysis
25.2 Celgene
25.2.1 Key Facts
25.2.2 Business Overview
25.2.3 Business Strategy
25.2.4 Business Segmentation by Revenue
25.2.5 Sales by Geography
25.2.6 Key Information
25.2.7 SWOT Analysis
25.3 Mesoblast
25.3.1 Key Facts
25.3.2 Business Overview
25.3.3 Therapeutic Areas
25.3.4 Geographical Segmentation
25.3.5 Business Strategy
25.3.6 Recent Developments
25.3.7 SWOT Analysis
25.4 Pluristem
25.4.1 Key Facts
25.4.2 Business Overview
25.4.3 Geographical Presence
25.4.4 Business Strategy
25.4.5 Recent Developments
25.4.6 SWOT Analysis

26.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Donor Evaluation before Collection of Cord Blood Cells
Exhibit 3: Collection of Cord Blood Cells
Exhibit 4: Processing and Storage Methods of Cord Blood Cells
Exhibit 5: Stem Cell Transplantations by Patient Race in US
Exhibit 6: Pipeline Portfolio of Stem Cell UCB Products for Different Diseases
Exhibit 7: Global Stem Cell UCB Market 2014-2019 ($ millions)
Exhibit 8: Global Stem Cell UCB Market Segment by Application
Exhibit 9: Global Stem Cell UCB Market Segmentation by Storage
Exhibit 10: Organizations and Initiatives Toward Biobank Harmonization
Exhibit 11: Key Factors Involved in Harmonization of Biobanks
Exhibit 12: Key Focus Areas in Harmonization of Biobanks
Exhibit 13: Organizations and Initiatives in Harmonizing Science and Infrastructure
Exhibit 14: Initiatives on Biobanking Resource Tools and Databases
Exhibit 15: Global Stem Cell UCB Market Segment by End-user
Exhibit 16: Segmentation of Global Stem Cell UCB Market by Geography 2014
Exhibit 17: Stem Cell UCB Market in Americas 2014-2019 ($ millions)
Exhibit 18: Stem Cell UCB Market in APAC 2014-2019 ($ millions)
Exhibit 19: Stem Cell UCB Market in APAC 2014-2019 ($ millions)
Exhibit 20: Statistics of Stem Cell UCB Market by Geography
Exhibit 21: Global Stem Cell UCB Market: Key Takeaways
Exhibit 22: Caladrious: Business Segmentation by Revenue 2014
Exhibit 23: Caladrious: Business Segmentation by Revenue 2013 and 2014 ($ millions)
Exhibit 24: Caladrious: Geographical Segmentation by Revenue 2014
Exhibit 25: Celgene: Business Segmentation by Revenue 2011-2013 ($ millions)
Exhibit 26: Celgene: Sales by Geography 2013
Exhibit 27: Mesoblast: Therapeutic Areas
Exhibit 28: Mesoblast: Geographical Segmentation
Exhibit 29: PLuristem: Geographical Presence



【掲載企業】

Caladrius Biosciences, Celgene, Mesoblast, Pluristem Therapeutics, Athersys, CHA Bio & Diostech, Cytori Therapeutics, Nuo Therapeutics, Ocata Therapeutics, Opexa Therapeutics, Osiris Therapeutics, Teva Pharmaceuticals, United Therapeutics


【資料のキーワード】

幹細胞臍帯血、臍帯血幹細胞治療、がん治療、血液疾患、代謝異常、免疫異常症、造血障害、遺伝性障害、臍帯血バンク

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[幹細胞臍帯血(UCB)の世界市場2015-2019] (Global Stem Cell Umbilical Cord Blood Market 2015-2019 / IRTNTR6649)販売に関する免責事項
[幹細胞臍帯血(UCB)の世界市場2015-2019] (Global Stem Cell Umbilical Cord Blood Market 2015-2019 / IRTNTR6649)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆